Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
Approximately 865 subjects (519 contezolid acefosamil/contezolid: 346 linezolid) will be enrolled with moderate or severe DFI that are confirmed or suspected to be due to a Gram-positive bacterial pathogen (MITT analysis set).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have diabetes mellitus (type 1 or 2) per the American Diabetes Association criteria
Have a foot infection that started at or below the malleolus and does not extend above the knee
Foot infection that meets the IWGDF DFI criteria for classification 3 (moderate infection) or 4 (severe infection)
Foot infection had acute onset or worsening of signs and symptoms within the past 14 days
You may not be if
Previous DFI known or suspected to be caused by Gram-positive pathogens that are resistant to oxazolidinone antibiotics
DFI with presumptive evidence or suspicion of osteomyelitis
Necrotizing fasciitis, crepitant cellulitis, wet gangrene, gas gangrene, ecthyma gangrenosum, septic arthritis, or severely impaired arterial supply to any portion of the affected foot which may need revascularization before the end of the study
Evidence of significant hepatic, renal, hematologic, or immunologic disease
Females who are pregnant or breastfeeding
Prior receipt of any formulation of contezolid acefosamil or contezolid
Inability to cooperate fully with the requirements of the study protocol, including the schedule of events, or likely to be noncompliant with any study requirements, or the Investigator determines that the subject should not participate in the study
Clareo Health | Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
